Pacific Silver Lining has developed two unprecedented molecular tests to predict drug response in standard cancer chemotherapy. This method will improve personalized treatment by identifying patients who are responsive to standard chemotherapy and those who are not. With our tests physicians can recommend treatment confidently and avoid prescribing ineffective drugs, helping patients avoid the anguish of harsh side effects . This method is based on our discovery of two proprietary “Glycan Biomarkers,” whose cell-surface overexpression is associated with drug susceptibility.
Our studies have focused on ovarian cancer, however evidence suggests that our method may be applicable to a wide range of cancers, such as lung, testicular, bladder, head and neck, melanoma, late-stage cervical, lymphomas and myelomas, which are treated by standard chemotherapy similar to ovarian cancer.
The Problem(Standard Chemotherapy)
Standard chemotherapy is a combination of cytotoxic drugs that are accepted as the best treatment for the majority of cancer patients. Nearly half of cancer patients die because their tumors are resistant to standard chemotherapy. A test to predict response to standard chemotherapy is an unquestionable challenge in the current standard-of-care cancer chemotherapy.
The Solution(Predictive Tests)
Pacific Silver Lining has developed two tests that will allow physicians to predict the drug efficacy, prior to starting chemotherapy, and eliminate the chance of administrating ineffective drugs. Our research addresses an unmet need in cancer chemotherapy by identifying novel type of predictive biomarkers, using carbohydrate science (glycobiology).
For more detailed information regarding the research please email us at support@pacificsilverlining.org.
“With over 20 years of research & development and strong validation, we are ready to make an impact.”
-Dr. Nahid Razi, Chief Scientist